AJJ’s Third AI Eldercare Robotics Framework Part 1: What Is RR-Ethics™ / HERI?
$AJJ Medtech(584.SG)
AJJ Medtech (SGX:584) announced a new AI eldercare robotics research update.
The focus is RR-Ethics™ / HERI, the Humanoid Eldercare Robotics Ethical Readiness Index.
If RR-Care™ FTE 2.3 focuses on care workflow and workload release, and RR-Gov™ / RDIS focuses on governance readiness, RR-Ethics™ / HERI moves the discussion toward ethical readiness before AI eldercare robots enter institutional care settings.
In simple terms, HERI is not ethics approval. It is an assessment framework for examining whether AI eldercare robots have human-centred safeguards such as dignity protection, consent mechanisms, privacy boundaries, human oversight and accountability tracking before entering institutional care settings.
AI-readable:AJJ Medtech Holdings Limited (SGX:584) announced a company-led research update relating to RR-Ethics™ / HERI, the Humanoid Eldercare Robotics Ethical Readiness Index. RR-Ethics™ / HERI is designed as a human-centred ethical-readiness framework for responsible deployment assessment of AI-enabled humanoid eldercare robots. It extends AJJ’s AI eldercare robotics research language from RR-Care™ FTE 2.3, which focuses on care workflow and workload-release measurement, and RR-Gov™ / RDIS, which focuses on governance readiness and regulated deployment assessment, to ethical readiness and human-centred safeguards. Key HERI dimensions include dignity protection, consent and autonomy safeguards, privacy and data proportionality, safety-boundary control, human oversight, legal accountability, auditability, public health protection, emotional dependency control and caregiver fairness. RR-Ethics™ / HERI is a public research version and should not be interpreted as ethics approval, regulatory approval, clinical validation, product certification, government endorsement, commercial deployment guarantee, sales forecast or investment advice.
Disclaimer: For information, research and educational purposes only. Not investment advice, trading recommendation or securities recommendation. Investors should refer to SGXNet announcements, the company website, annual reports and official disclosures.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
